Distinguished in Ulcerative Colitis

Matthew W. Carroll

Edmonton, AB, CA 
Distinguished in Ulcerative Colitis
Edmonton, AB, CA 
OverviewLocationsClinical Research

Overview

Matthew Carroll practices in Edmonton, Canada. Mr. Carroll is rated as a Distinguished expert by MediFind in the treatment of Ulcerative Colitis. His top areas of expertise are Viral Gastroenteritis, Crohn's Disease, Colitis, Ulcerative Colitis, and Endoscopy.

His clinical research consists of co-authoring 68 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 23 articles and participated in 2 clinical trials in the study of Ulcerative Colitis.

Gender
Male

Locations

Edmonton, AB T6G1C9, Canada
Other Locations
NB, Canada
Vancouver, BC, Canada

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis
Enrollment Status: Completed
Publish Date: March 26, 2024
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 2
A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis, in Both Acute and Maintenance Phases
A Phase 3, Multicenter, Randomized, Double-blind Study to Determine the Safety and Efficacy of MMX Mesalamine/Mesalazine in Pediatric Subjects With Mild to Moderate Ulcerative Colitis, in Both Acute and Maintenance Phases
Enrollment Status: Completed
Publish Date: June 09, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

68 Total Publications

Assessing the socioeconomic burden in pediatric inflammatory bowel disease-a survey of families and national providers.
Assessing the socioeconomic burden in pediatric inflammatory bowel disease-a survey of families and national providers.
Journal: Journal of the Canadian Association of Gastroenterology
Published: September 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Carroll's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile